R21 grant awarded to develop a tool to predict a patient’s risk of developing a metastatic brain tumor

An NIH grant has been awarded to the lab and Dr. Merajver’s lab to predict a patient risk of developing metastatic brain tumor. The Merajver lab and Oliver lab at the University of Michigan have been awarded an R21 grant by the National Institute of Health with the title “Artificial Intelligence driven prediction of brain metastasis from primary tumor sites at diagnosis”. The interdisciplinary team consists of Dr. Sofia Merajver, Dr. Ryan Oliver, Dr. Trisha Westerhof, Dr. Maria Castro, Dr. Aki Morikawa and Dr. Carlos Aguilar. The goal is to develop a technology that identifies patients at risk of developing metastatic brain tumors early enough that personalized preventative measures can be taken.